The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster

References

• COVID-19 data explorer - our world in data; 2022. Available from: https://ourworldindata.org/explorers/coronavirus-data-explorer. Accessed December 16, 2022.
   Google Scholar
• Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–758. doi:10.1136/postgradmedj-2020-138234
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Patil S, Subramaniam N, Sharma R. COVID-19 vaccine hesitancy and resistance in India explored through a population-based longitudinal survey. Vaccines. 2021;9(10):1064. doi:10.3390/vaccines9101064
   Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Eyre DW, Lumley SF, Wei J, et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and oxford–AstraZeneca vaccines by previous infection status. Clin Microbiol Infect. 2021;27(10):1516.e7–1516.e14. doi:10.1016/j.cmi.2021.05.041
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384:1576–1578. doi:10.1056/NEJMc2036242
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Lawrence S. Predictors of COVID-19 vaccine hesitancy in Germany: a cross-sectional, population-based study. Postgrad Med J. 2022;98(1164):756–764. doi:10.1136/postgradmedj-2021-141365
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Senthil S, John S, et al. The protective role of statins in COVID-19 patients: a retrospective observational study. Transl Med Commun. 2021;6. doi:10.1186/s41231-021-00102-4
   Google Scholar
• Umakanthan S, Bukelo MM, Gajula SS. The Commonwealth Caribbean COVID-19: regions resilient pathway during pandemic. Front Public Health. 2022;10:1288. doi:10.3389/fpubh.2022.844333
   Web of Science ®Google Scholar
• Raport zakażeń koronawirusem (SARS-CoV-2) - Koronawirus: informacje i zalecenia - Portal Gov.pl; 2022. Available from: https://www.gov.pl/web/koronawirus/wykaz-zarazen-koronawirusem-sars-cov-2. Accessed December 16, 2022.
   Google Scholar
• Lee N, Jeong S, Lee SK, et al. Quantitative analysis of anti-N and anti-S antibody titers of SARS-CoV-2 infection after the third dose of COVID-19 vaccination. Vaccines. 2022;10(7):1143. doi:10.3390/vaccines10071143
   Web of Science ®Google Scholar
• Elecsys® Anti-SARS-CoV-2; 2022. Available from: https://diagnostics.roche.com/gb/en/products/params/elecsys-anti-sars-cov-2.html. Accessed December 16, 2022.
   Google Scholar
• Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell. 2020;184:169–183.e17. doi:10.1016/j.cell.2020.11.029
   PubMed Web of Science ®Google Scholar
• Angyal A, Longet S, Moore SC, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe. 2021;3:e21–e31. doi:10.1016/S2666-5247(21)00275-5
   Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186–193. doi:10.1038/s41590-021-01122-w
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6(1):1–13. doi:10.1038/s41541-021-00369-6
   Web of Science ®Google Scholar
• Hansen CB, Jarlhelt I, Pérez-Alós L, et al. SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals. J Immunol. 2021;206:109–117. doi:10.4049/jimmunol.2000898
   PubMed Web of Science ®Google Scholar
• Fujigaki H, Inaba M, Osawa M, et al. Comparative analysis of antigen-specific anti–SARS-CoV-2 antibody isotypes in COVID-19 patients. J Immunol. 2021;206:2393–2401. doi:10.4049/jimmunol.2001369
   Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, Phase 2 trial. Lancet. 2021;398:2258–2276. doi:10.1016/S0140-6736(21)02717-3
   PubMed Web of Science ®Google Scholar
• Wolszczak-Biedrzycka B, Bié Nkowska A, Dorf J, Leitão JH. Assessment of post-vaccination antibody response eight months after the administration of BNT1622b2 vaccine to healthcare workers with particular emphasis on the impact of previous COVID-19 infection. Vaccines. 2021;9:1508. doi:10.3390/vaccines9121508
   Web of Science ®Google Scholar
• Wolszczak-Biedrzycka B, Bieńkowska A, Zaborowska JE, Smolińska-Fijołek E, Biedrzycki G, Dorf J. Anti-SARS-CoV-2S antibody levels in healthcare workers 10 months after the administration of two BNT162b2 vaccine doses in view of demographic characteristic and previous COVID-19 Infection. Vaccines. 2022;10(5):741. doi:10.3390/vaccines10050741
   Web of Science ®Google Scholar
• Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9(11):1255–1265. doi:10.1016/S2213-2600(21)00357-X
   PubMed Web of Science ®Google Scholar
• Groß R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine. 2022;75:103761. doi:10.1016/j.ebiom.2021.103761
   PubMed Web of Science ®Google Scholar
• Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A. Humoral immune response after different SARS-CoV-2 vaccination regimens. BMC Med. 2022;20(1). doi:10.1186/s12916-021-02231-x
   Web of Science ®Google Scholar
• Soytas RB, Cengiz M, Islamoglu MS, et al. Antibody responses to COVID-19 vaccines in older adults. J Med Virol. 2021.
   Web of Science ®Google Scholar
• Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94(1):39–41. doi:10.1002/jmv.27350
   PubMed Web of Science ®Google Scholar
• Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–1057. doi:10.1056/NEJMoa2116414
   PubMed Web of Science ®Google Scholar
• Faustini SE, Shields AM, Banham G, et al. Cross reactivity of spike glycoprotein induced antibody against delta and omicron variants before and after third SARS-CoV-2 vaccine dose. medRxiv. 2022;2021:1.
   Google Scholar
• Aldridge RW, Yavlinsky A, Nguyen V, et al. Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort. medRxiv. 2021;2021. doi:10.1101/2021.11.05.21265968v1
   Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891. doi:10.1016/S0140-6736(21)00432-3
   PubMed Web of Science ®Google Scholar
• Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6(9):1140–1149. doi:10.1038/s41564-021-00947-3
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385(7):585–594. doi:10.1056/NEJMoa2108891
   PubMed Web of Science ®Google Scholar
• Ward H, Cooke G, Whitaker M, et al. REACT-2 round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. medRxiv. 2021;2021. doi:10.1101/2021.02.26.21252512v1
   Google Scholar
• Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043–2046. doi:10.1016/S0140-6736(21)01115-6
   PubMed Web of Science ®Google Scholar
• Falsey A, Frenck R, Walsh E, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385(17):1627–1629. doi:10.1056/NEJMc2113468
   PubMed Web of Science ®Google Scholar
• Flaxman A, Marchevsky N, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021;398(10304):981–990. doi:10.1016/S0140-6736(21)01699-8
   PubMed Web of Science ®Google Scholar
• Li J, Hou L, Guo X, et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv. 2021. doi:10.1101/2021.09.03.21263062
   Google Scholar
• Ward H, Whitaker M, Flower B, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):1–6. doi:10.1038/s41467-022-28527-x
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2018;36(36):5350–5357. doi:10.1016/j.vaccine.2017.07.062
   PubMed Web of Science ®Google Scholar
• Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397(10280):1178–1181. doi:10.1016/S0140-6736(21)00502-X
   PubMed Web of Science ®Google Scholar